Enhanced immune response in porcine species

Patent metadata

Field	Value
Publication number	US-11439703-B2
Application number	US-201615748444-A
Country	US
Kind code	B2
Filing date	Jul 28, 2016
Priority date	Jul 31, 2015
Publication date	Sep 13, 2022
Grant date	Sep 13, 2022

Abstract

The present invention generally relates to methods of eliciting an immune response in a porcine species subject. In particular, an immunomodulator composition is used to induce an immune response to enhance the subject's ability to fight infectious pathogens.

First claim

What is claimed is:

1. A method of treating an infection in a recipient food production swine comprising administering an effective amount of an immunomodulator composition to the food production swine, wherein the immunomodulator composition comprises: (a) a nucleic acid sequence having at least 94% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 4, wherein the nucleic acid sequences comprises at least 280 CpG dinucleotides; and (b) a cationic liposome delivery vehicle, wherein the cationic liposome delivery vehicle comprises pairs of lipids selected from the group consisting of N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) and cholesterol; N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTAP) and cholesterol; 1-[2-(oleoyloxy)ethyl]-2-oleyl-3-(2-hydroxyethyl) imidazolinium chloride (DOTIM) and cholesterol; and dimethyldioctadecylammonium bromide (DDAB) and cholesterol;
wherein the immunomodulator composition further comprises or is administered in combination with an immunogen derived from an infectious agent causing the infection, and wherein an immune response to the immunogen is increased in the food production swine with the combination as compared to the immune response in the food production swine elicited with the immunogen by itself.

2. The method of claim 1 , wherein the administration is before exposure to the infectious agent comprising the immunogen.

3. The method of claim 1 , wherein the administration is after exposure to the infectious agent comprising the immunogen.

4. The method of claim 1 , wherein the immunogen is comprised in a vaccine.

5. The method of claim 1 , wherein the immunomodulator composition further comprises a pharmaceutically acceptable carrier.

6. The method of claim 4 , wherein the vaccine is a Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) vaccine or Escherichia coli vaccine.

7. The method of claim 1 , wherein the immunomodulator composition is administered intramuscularly in a single dose.

8. The method of claim 1 , wherein the immunogen is derived from Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) or Escherichia coli.

9. The method of claim 8 , wherein the immunogen is derived from PRRSV.

Assignees

• Bayer Animal Health Gmbh
• Elanco Us Inc

Inventors

• Abraham Albert
• Nickell Jason
• Keil Daniel
• Weiss Christian

Classifications

• A61K2039/55555

  Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers · CPC title

• A61K2039/55561

  CpG containing adjuvants; Oligonucleotide containing adjuvants · CPC title

• A61K39/39 Primary

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title

• A61K2039/552

  Veterinary vaccine · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title